LIFTT invests in Keyron’s anti-diabetes and obesity device

Your browser does not seem to support iframes. <a href="https://flowpaper.com/flipbook/?pdf=https://www.liftt.com/wp-content/uploads/2021/12/2021-12-22_LIFTT_PR_LIFTT_invests_in_Keyron-EN.pdf?wp-hosted=1" target="_blank">Click here to read this PDF</a>.

Created using FlowPaper Flipbook Maker ↗

LIFTT Venture Capital Italia2022-12-29T15:51:22+01:0022 December 2021|

FIND OUT MORE

Media Centre
Investor Relations
Careers Centre
Our Commitment
Contact

HEADQUARTER

OGR Tech
Corso Castelfidardo 22
10138 Torino TO

INFORMAZIONI

VAT n. 12013790014

Shared Capital
€ 100.835.954,00 authorised,
€ 60.223.243,00 paid,
€ 60.223.243,00 as per last statutory financial statements.

LIFTT S.p.A. adopts an Organization, Management and Control Model in line with the provisions of Legislative Decree 231/2001, and the Code of Ethics as completing part of the Model.

This site uses its own cookies to ensure a better experience on the site. By continuing to browse you agree to their use.
More information, including directions on how to remove cookies and refuse their use. Accetta Rifiuta

LIFTT invests in Keyron’s anti-diabetes and obesity device

Share

FIND OUT MORE

HEADQUARTER

INFORMAZIONI

© Copyright 2019 – 2024 | All Rights Reserved